{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T03:48:23Z","timestamp":1789098503341,"version":"build-2803163510"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>HER2 expression has a prognostic and predictive impact in early-stage breast cancer (BC). HER2 positive BC (immunohistochemistry (IHC) score 3\u2009+\u2009or 2\u2009+\u2009with in situ hybridization (ISH) amplification) are treated with HER2 targeted therapies. The concept of HER2-low BC (IHC score 1\u2009+\u2009or 2\u2009+\u2009without ISH amplification) is drawing attention as anti-HER2 treatment has recently shown efficacy in this subgroup. We aimed to explore the response to neoadjuvant chemotherapy (NAC) in HER2-low early BC according to the HER2 score (1\u2009+\u2009or 2\u2009+\u2009without amplification).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a retrospective study in two French comprehensive cancer centers. All patients with HER2-low BC treated with NAC from January 2014 to December 2020 were included. The primary objective was to analyze the pathological complete response (pCR) rate to NAC using the Sataloff or RCB system, according to the HER2 score. Secondary objectives were to assess disease free survival (DFS), overall survival (OS) and to explore the immune environment through the Neutrophil-to-Lymphocyte Ratio (NLR), according to HER2 expression. Univariate and multivariate analyses were performed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We included 237 tumors for 229 patients. Of these, 160 (67.5%) tumors were HER2 1\u2009+\u2009, 77 (32.5%) were HER2 2\u2009+\u2009, and 152 (64.1%) were hormone receptor (HR) positive. The median age was 53.9\u00a0years. No differences in tumor characteristics were observed between HER2 1\u2009+\u2009and HER2 2\u2009+\u2009subgroups. pCR was achieved in 38 tumors (17%), without any difference between HER2 1\u2009+\u2009and HER2 2\u2009+\u2009subgroups (<jats:italic>p<\/jats:italic>\u2009=\u20090.77). DFS and OS were significantly different between HER2 1\u2009+\u2009and HER2 2\u2009+\u2009patients (HR\u2009=\u20090.41,CI95%[0.17;0.97] <jats:italic>p<\/jats:italic>\u2009=\u20090.037 and HR\u2009=\u20090.31,CI95%[0.09;1.02] <jats:italic>p<\/jats:italic>\u2009=\u20090.042, respectively). HER2 status was still associated with DFS and OS after adjustment for age, HR status and NLR, with better outcomes in favor of HER2 score 2\u2009+\u2009(HR\u2009=\u20090.35 [0.15\u20130.84] and HR\u2009=\u20090.24 [0.07\u20130.81], respectively). NLR was not associated with worse DFS or OS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In HER2-low early BC, no differences in pCR were observed between HER2 1\u2009+\u2009and HER2 2\u2009+\u2009tumors, however patients with HER2 2\u2009+\u2009tumors had a better DFS and OS than those with HER2 1\u2009+\u2009. Further investigations are needed to describe the intrinsic differences in the spectrum of HER2-low BC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-022-10163-9","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T13:04:27Z","timestamp":1666271067000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer"],"prefix":"10.1186","volume":"22","author":[{"given":"Fran\u00e7ois","family":"Cherifi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang\u00e9lique","family":"Da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Blanc-Fournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Abramovici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonin","family":"Broyelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djelila","family":"Allouache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioana","family":"Hrab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine","family":"Segura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeline","family":"Morel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maud","family":"Villemin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence","family":"Boscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coraline","family":"Dubot-Poitelon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Rottier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Lequesne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Emile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,20]]},"reference":[{"key":"10163_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"10163_CR2","doi-asserted-by":"publisher","first-page":"10869","DOI":"10.1073\/pnas.191367098","volume":"98","author":"T Sorlie","year":"2001","unstructured":"Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci. 2001;98:10869\u201374.","journal-title":"Proc Natl Acad Sci"},{"key":"10163_CR3","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science. 1987;235:177\u201382.","journal-title":"Science"},{"key":"10163_CR4","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1158\/1055-9965.EPI-17-0627","volume":"27","author":"N Howlader","year":"2018","unstructured":"Howlader N, Cronin K, Kurian A, Andridge R. Differences in breast cancer survival by molecular subtypes in the United States. Cancer Epidemiol Biomarkers Prev. 2018;27:619\u201326. https:\/\/doi.org\/10.1158\/1055-9965.EPI-17-0627.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10163_CR5","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.breast.2013.11.011","volume":"23","author":"MC Figueroa-Magalh\u00e3es","year":"2014","unstructured":"Figueroa-Magalh\u00e3es MC, Jelovac D, Connolly R, Wolff AC. Treatment of HER2-positive breast cancer. Breast. 2014;23:128\u201336. https:\/\/doi.org\/10.1016\/j.breast.2013.11.011.","journal-title":"Breast"},{"key":"10163_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","volume":"17","author":"D-Y Oh","year":"2020","unstructured":"Oh D-Y, Bang Y-J. HER2-targeted therapies \u2014 a role beyond breast cancer. Nat Rev Clin Oncol. 2020;17:33\u201348. https:\/\/doi.org\/10.1038\/s41571-019-0268-3.","journal-title":"Nat Rev Clin Oncol"},{"key":"10163_CR7","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.3390\/cancers13071664","volume":"13","author":"AD Ricci","year":"2021","unstructured":"Ricci AD, Rizzo A, Rojas Llimpe FL, Di Fabio F, De Biase D, Rihawi K. Novel HER2-directed treatments in advanced gastric carcinoma: AnotHER paradigm shift? Cancers. 2021;13:1664. https:\/\/doi.org\/10.3390\/cancers13071664.","journal-title":"Cancers"},{"key":"10163_CR8","doi-asserted-by":"publisher","first-page":"S02426498210019","DOI":"10.1016\/j.annpat.2021.07.014","volume":"2021","author":"C Franchet","year":"2021","unstructured":"Franchet C, Djerroudi L, Maran-Gonzalez A, Abramovici O, Antoine M, Becette V, Mise \u00e0 jour, et al. des recommandations du GEFPICS pour l\u2019\u00e9valuation du statut HER2 dans les cancers infiltrants du sein en France. Ann Pathol. 2021;2021:S0242649821001917. https:\/\/doi.org\/10.1016\/j.annpat.2021.07.014.","journal-title":"Ann Pathol"},{"key":"10163_CR9","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1200\/JOP.18.00206","volume":"14","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH, Harvey BE, McShane LM, Dowsett M. HER2 testing in breast cancer: american society of clinical oncology\/college of American pathologists clinical practice guideline focused update summary. JOP. 2018;14:437\u201341. https:\/\/doi.org\/10.1200\/JOP.18.00206.","journal-title":"JOP"},{"key":"10163_CR10","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1200\/JCO.1999.17.7.1983","volume":"17","author":"T Jacobs","year":"1999","unstructured":"Jacobs T, Gown A, Yaziji H, Barnes M, Schnitt S. Specificity of HercepTest in determining HER-2\/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol. 1999;17:1983\u20137. https:\/\/doi.org\/10.1200\/JCO.1999.17.7.1983.","journal-title":"J Clin Oncol"},{"key":"10163_CR11","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1634\/theoncologist.3-4-237","volume":"3","author":"J Ross","year":"1998","unstructured":"Ross J, Fletcher J. The HER-2\/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist. 1998;3:237\u201352.","journal-title":"Oncologist"},{"key":"10163_CR12","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"A Wolff","year":"2018","unstructured":"Wolff A, Hammond M, Allison K, Harvey B, Mangu P, Bartlett J, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology\/college of American pathologists clinical practice guideline focused update. J Clin Oncol. 2018;36:2105\u201322. https:\/\/doi.org\/10.1200\/JCO.2018.77.8738.","journal-title":"J Clin Oncol"},{"key":"10163_CR13","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1200\/JCO.19.02488","volume":"38","author":"P Tarantino","year":"2020","unstructured":"Tarantino P, Hamilton E, Tolaney SM, Cortes J, Morganti S, Ferraro E, et al. HER2-Low breast cancer: Pathological and clinical landscape. J Clin Oncol. 2020;38:1951\u201362. https:\/\/doi.org\/10.1200\/JCO.19.02488.","journal-title":"J Clin Oncol"},{"key":"10163_CR14","doi-asserted-by":"publisher","first-page":"213","DOI":"10.5858\/arpa.2012-0617-OA","volume":"138","author":"K Schalper","year":"2014","unstructured":"Schalper K, Kumar S, Hui P. A retrospective population-based comparison of HER2 immunohistochemistry and fluorescence in situ hybridization in breast carcinomas: Impact of 2007 American society of clinical oncology\/college of american pathologists criteria. Arch Pathol Lab Med. 2014;138:213\u20139.","journal-title":"Arch Pathol Lab Med"},{"key":"10163_CR15","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","volume":"30","author":"F Cardoso","year":"2019","unstructured":"Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30:1194\u2013220. https:\/\/doi.org\/10.1093\/annonc\/mdz173.","journal-title":"Ann Oncol"},{"key":"10163_CR16","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1309\/AJCP4A7KTAYHZSOE","volume":"140","author":"K Lambein","year":"2013","unstructured":"Lambein K, Van Bockstal M, Vandemaele L, Geenen S, Rottiers I, Nuyts A, et al. Distinguishing score 0 from score 1+ in HER2 immunohistochemistry-negative breast cancer. Am J Clin Pathol. 2013;140:561\u20136. https:\/\/doi.org\/10.1309\/AJCP4A7KTAYHZSOE.","journal-title":"Am J Clin Pathol"},{"key":"10163_CR17","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1634\/theoncologist.2012-0194","volume":"17","author":"V Rossi","year":"2012","unstructured":"Rossi V, Sarotto I, Maggiorotto F, Berchialla P, Kubatzki F, Tomasi N, et al. Moderate immunohistochemical expression of HER-2 (2+) without HER-2 gene amplification is a negative prognostic factor in early breast cancer. Oncologist. 2012;17:1418\u201325. https:\/\/doi.org\/10.1634\/theoncologist.2012-0194.","journal-title":"Oncologist"},{"key":"10163_CR18","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1097\/PAS.0b013e31819437f9","volume":"33","author":"M Gilcrease","year":"2009","unstructured":"Gilcrease M, Woodward W, Nicolas M, Corley L, Fuller G, Esteva F, et al. Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer. Am J Surg Pathol. 2009;33:759\u201367. https:\/\/doi.org\/10.1097\/PAS.0b013e31819437f9.","journal-title":"Am J Surg Pathol"},{"key":"10163_CR19","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1530\/ERC-15-0335","volume":"22","author":"H Eggemann","year":"2015","unstructured":"Eggemann H, Ignatov T, Burger E, Kantelhardt EJ, Fettke F, Thomssen C, et al. Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer. Endocr Relat Cancer. 2015;22:725\u201333. https:\/\/doi.org\/10.1530\/ERC-15-0335.","journal-title":"Endocr Relat Cancer"},{"key":"10163_CR20","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s10549-019-05505-4","volume":"179","author":"MH Kim","year":"2020","unstructured":"Kim MH, Kim GM, Kim JH, Kim JY, Park HS, Park S, et al. Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and older. Breast Cancer Res Treat. 2020;179:687\u201397. https:\/\/doi.org\/10.1007\/s10549-019-05505-4.","journal-title":"Breast Cancer Res Treat"},{"key":"10163_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41523-020-00208-2","volume":"7","author":"F Schettini","year":"2021","unstructured":"Schettini F, Chic N, Bras\u00f3-Maristany F, Par\u00e9 L, Pascual T, Conte B, et al. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. Npj Breast Cancer. 2021;7:1. https:\/\/doi.org\/10.1038\/s41523-020-00208-2.","journal-title":"Npj Breast Cancer"},{"key":"10163_CR22","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1200\/JCO.19.01455","volume":"38","author":"L Fehrenbacher","year":"2020","unstructured":"Fehrenbacher L, Cecchini RS, Geyer CE, Rastogi P, Costantino JP, Atkins JN, et al. NSABP B-47\/NRG oncology phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2+. J Clin Oncol. 2020;38:444\u201353. https:\/\/doi.org\/10.1200\/JCO.19.01455.","journal-title":"J Clin Oncol"},{"key":"10163_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.111682","volume":"183","author":"Z Xu","year":"2019","unstructured":"Xu Z, Guo D, Jiang Z, Tong R, Jiang P, Bai L, et al. Novel HER2-targeting antibody-drug conjugates of trastuzumab beyond T-DM1 in breast cancer: trastuzumab deruxtecan(DS-8201a) and (Vic-)trastuzumab duocarmazine (SYD985). Eur J Med Chem. 2019;183: 111682. https:\/\/doi.org\/10.1016\/j.ejmech.2019.111682.","journal-title":"Eur J Med Chem"},{"key":"10163_CR24","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1200\/JCO.19.02318","volume":"38","author":"S Modi","year":"2020","unstructured":"Modi S, Park H, Murthy R, Iwata H, Tamura K, Tsurutani J, et al. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase ib study. J Clin Oncol. 2020;38:1887\u201396. https:\/\/doi.org\/10.1200\/JCO.19.02318.","journal-title":"J Clin Oncol"},{"key":"10163_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022;387:9\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2203690.","journal-title":"N Engl J Med."},{"key":"10163_CR26","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.1016\/j.clbc.2020.08.006","volume":"21","author":"A Andrikopoulou","year":"2021","unstructured":"Andrikopoulou A, Zografos E, Liontos M, Koutsoukos K, Dimopoulos M-A, Zagouri F. Trastuzumab deruxtecan (DS-8201a): the latest research and advances in breast cancer. Clin Breast Cancer. 2021;21:e212\u20139. https:\/\/doi.org\/10.1016\/j.clbc.2020.08.006.","journal-title":"Clin Breast Cancer"},{"key":"10163_CR27","doi-asserted-by":"publisher","first-page":"9823","DOI":"10.1007\/s13277-014-2282-5","volume":"35","author":"YW Koh","year":"2014","unstructured":"Koh YW, Lee HJ, Ahn J-H, Lee JW, Gong G. Prognostic significance of the ratio of absolute neutrophil to lymphocyte counts for breast cancer patients with ER\/PR-positivity and HER2-negativity in neoadjuvant setting. Tumor Biol. 2014;35:9823\u201330. https:\/\/doi.org\/10.1007\/s13277-014-2282-5.","journal-title":"Tumor Biol"},{"key":"10163_CR28","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.31557\/APJCP.2019.20.7.2209","volume":"20","author":"M Rivas","year":"2019","unstructured":"Rivas M, Acevedo F, Dominguez F, Galindo H, Camus M, Oddo D, et al. The neutrophil to lymphocyte ratio predicts the response to neoadjuvant chemotherapy in luminal B breast cancer. Asian Pac J Cancer Prev. 2019;20:2209\u201312. https:\/\/doi.org\/10.31557\/APJCP.2019.20.7.2209.","journal-title":"Asian Pac J Cancer Prev."},{"key":"10163_CR29","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, Mehta K, Costantino J, Wolmark N. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164\u201372.","journal-title":"Lancet"},{"key":"10163_CR30","first-page":"297","volume":"180","author":"S Dm","year":"1995","unstructured":"Dm S, Ba M, Aj P, Ul S, Cp L, Z B. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg. 1995;180:297\u2013306.","journal-title":"J Am Coll Surg."},{"key":"10163_CR31","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","volume":"25","author":"WF Symmans","year":"2007","unstructured":"Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. JCO. 2007;25:4414\u201322. https:\/\/doi.org\/10.1200\/JCO.2007.10.6823.","journal-title":"JCO"},{"key":"10163_CR32","unstructured":"Download R-4.2.0 for Windows. The R-project for statistical computing. n.d. https:\/\/cran.r-project.org\/bin\/windows\/base\/ (Accessed 1 Jun 2022)."},{"key":"10163_CR33","unstructured":"sein.herfrance.net n.d. http:\/\/sein.herfrance.net\/ (Accessed 1 Jun 2022)."},{"key":"10163_CR34","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/S1470-2045(21)00301-6","volume":"22","author":"C Denkert","year":"2021","unstructured":"Denkert C, Seither F, Schneeweiss A, Link T, Blohmer J-U, Just M, et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 2021;22:1151\u201361. https:\/\/doi.org\/10.1016\/S1470-2045(21)00301-6.","journal-title":"Lancet Oncol"},{"key":"10163_CR35","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1158\/1078-0432.CCR-19-3492","volume":"26","author":"LM Spring","year":"2020","unstructured":"Spring LM, Fell G, Arfe A, Sharma C, Greenup R, Reynolds KL, et al. Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis. Clin Cancer Res. 2020;26:2838\u201348. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3492.","journal-title":"Clin Cancer Res"},{"key":"10163_CR36","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration Oncology Center of Excellence Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) July 2020 Clinical\/Medical Revision 1. Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval Guidance for Industry n.d. https:\/\/www.fda.gov\/media\/83507\/download (Accessed 24 Oct 2021)."},{"key":"10163_CR37","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.annonc.2021.06.023","volume":"32","author":"HJ Burstein","year":"2021","unstructured":"Burstein HJ, Curigliano G, Th\u00fcrlimann B, Weber WP, Poortmans P, Regan MM, et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Annals of Oncology. 2021;32:1216\u201335. https:\/\/doi.org\/10.1016\/j.annonc.2021.06.023.","journal-title":"Annals of Oncology."},{"key":"10163_CR38","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-021-06365-7","author":"LL de Moura","year":"2021","unstructured":"de Moura LL, Cesca MG, Tavares MC, Santana DM, Saldanha EF, Guimar\u00e3es PT, et al. HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer. Breast Cancer Res Treat. 2021. https:\/\/doi.org\/10.1007\/s10549-021-06365-7.","journal-title":"Breast Cancer Res Treat"},{"key":"10163_CR39","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1200\/JCO.2019.37.15_suppl.3133","volume":"37","author":"JD Wulfkuhle","year":"2019","unstructured":"Wulfkuhle JD, Wolf DM, Yau C, Gallagher RI, Brown Swigart L, Hirst GL, et al. HER family protein expression and activation predicts response to combination T-DM1\/pertuzumab in HER2+ patients in the I-SPY 2 TRIAL. JCO. 2019;37:3133\u20133133. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.3133.","journal-title":"JCO"},{"key":"10163_CR40","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1159\/000354253","volume":"8","author":"M Giuliano","year":"2013","unstructured":"Giuliano M, Trivedi MV, Schiff R. Bidirectional crosstalk between the estrogen receptor and human epidermal growth factor receptor 2 signaling pathways in breast cancer: molecular basis and clinical implications. Breast Care. 2013;8:256\u201362. https:\/\/doi.org\/10.1159\/000354253.","journal-title":"Breast Care"},{"key":"10163_CR41","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1093\/jnci\/djh166","volume":"96","author":"J Shou","year":"2004","unstructured":"Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2\/neu cross-talk in ER\/HER2-positive breast cancer. J Natl Cancer Inst. 2004;96:926\u201335. https:\/\/doi.org\/10.1093\/jnci\/djh166.","journal-title":"J Natl Cancer Inst"},{"key":"10163_CR42","doi-asserted-by":"publisher","first-page":"55","DOI":"10.4048\/jbc.2013.16.1.55","volume":"16","author":"H Noh","year":"2013","unstructured":"Noh H, Eomm M, Han A. Usefulness of pretreatment neutrophil to lymphocyte ratio in predicting disease-specific survival in breast cancer patients. J Breast Cancer. 2013;16:55. https:\/\/doi.org\/10.4048\/jbc.2013.16.1.55.","journal-title":"J Breast Cancer"},{"key":"10163_CR43","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1200\/JCO.2019.37.15_suppl.502","volume":"37","author":"O Metzger Filho","year":"2019","unstructured":"Metzger Filho O, Viale G, Trippa L, Li T, Yardley DA, Mayer IA, et al. HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: results from a prospective clinical trial. JCO. 2019;37:502\u2013502. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.502.","journal-title":"JCO"},{"key":"10163_CR44","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1002\/1878-0261.12375","volume":"12","author":"IH Rye","year":"2018","unstructured":"Rye IH, Trinh A, S\u00e6tersdal AB, Nebdal D, Lingj\u00e6rde OC, Almendro V, et al. Intratumor heterogeneity defines treatment-resistant HER 2+ breast tumors. Mol Oncol. 2018;12:1838\u201355. https:\/\/doi.org\/10.1002\/1878-0261.12375.","journal-title":"Mol Oncol"},{"key":"10163_CR45","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.3390\/cancers13051015","volume":"13","author":"D Eiger","year":"2021","unstructured":"Eiger D, Agostinetto E, Sa\u00fade-Conde R, de Azambuja E. The exciting new field of HER2-low breast cancer treatment. Cancers. 2021;13:1015. https:\/\/doi.org\/10.3390\/cancers13051015.","journal-title":"Cancers"},{"key":"10163_CR46","doi-asserted-by":"publisher","first-page":"834651","DOI":"10.3389\/fmolb.2022.834651","volume":"9","author":"K Venetis","year":"2022","unstructured":"Venetis K, Crimini E, Sajjadi E, Corti C, Guerini-Rocco E, Viale G, et al. HER2 low, ultra-low, and novel complementary biomarkers: expanding the spectrum of HER2 positivity in breast cancer. Front Mol Biosci. 2022;9:834651. https:\/\/doi.org\/10.3389\/fmolb.2022.834651.","journal-title":"Front Mol Biosci"},{"key":"10163_CR47","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, et al. sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384:1529\u201341. https:\/\/doi.org\/10.1056\/NEJMoa2028485.","journal-title":"N Engl J Med"},{"key":"10163_CR48","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s12282-021-01303-3","volume":"29","author":"N Horisawa","year":"2022","unstructured":"Horisawa N, Adachi Y, Takatsuka D, Nozawa K, Endo Y, Ozaki Y, et al. The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status. Breast Cancer. 2022;29:234\u201341. https:\/\/doi.org\/10.1007\/s12282-021-01303-3.","journal-title":"Breast Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10163-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-10163-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10163-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T13:06:33Z","timestamp":1666271193000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-10163-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,20]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["10163"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-10163-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,20]]},"assertion":[{"value":"8 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is research that \u201cResearch not involving Human participants\u201d of the French Public Health Code, articles 53 of the Data Protection Act, and respects the MR04 standards and have been performed in accordance with the Declaration of Helsinki. The study was approved by the institutional review board of the cancer center Fran\u00e7ois Baclesse, Caen, France. Is registered to the French Health Data Hub under the reference N\u00b0 F20210125175632.The promoter: The cancer center Fran\u00e7ois Baclesse, Caen, France, complies with the regulations in force, in particular the rights of persons subject to processing within the meaning of EU Regulation No. 2016\/679 on data protection (\u201cRGPD\u201d).Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1081"}}